氟轻松玻璃体内植入剂作为糖尿病黄斑水肿基线治疗的随机4期NEW DAY研究
NEW DAY研究评估0.19 mg氟轻松玻璃体内植入剂作为糖尿病黄斑水肿基线治疗的疗效与安全性。306例患者随机接受FAc植入剂或阿柏西普负荷剂量治疗,主要终点补救注射次数两组无显著差异(2.4 vs 2.5,P=0.76),但FAc组总注射次数更少、首次补救注射时间更长,视力和中央亚区厚度改善相似,白内障手术和眼压升高比例更高。
要点
- FAc组与阿柏西普组补救注射次数无显著差异(2.4 vs 2.5,P=0.76),主要终点未达到优效性。
- FAc组总注射次数更少(3.4 vs 7.2,名义P<0.001),首次补救注射时间更长(185.4 vs 132.8天,名义P<0.001)。
- FAc组白内障手术(27.9% vs 6.6%)和眼压升高(15.6% vs 3.3%)比例更高。
核心结论
- FAc植入剂作为DME基线治疗未在补救注射次数上优于阿柏西普,但以不到一半的总注射次数达到相似的视力和解剖学改善。
研究设计与样本
- 前瞻性、随机、单盲、活性对照、多中心、18个月、4期研究,共306例中心受累型DME成人患者随机分组。
主要发现
- 平均补救注射次数FAc组2.4次(SD 3.2)vs 阿柏西普组2.5次(SD 3.1),P=0.76。
- 总注射次数(含方案规定和补救)FAc组平均3.4次(SD 3.2)vs 阿柏西普组7.2次(SD 3.4),名义P<0.001。
- 首次补救注射时间FAc组平均185.4天(SD 97.9)vs 阿柏西普组132.8天(SD 94.0),名义P<0.001。
- 未接受补救注射的比例两组相似(32.5% vs 30.3%,名义P=0.68)。
- BCVA平均变化1.8字母 vs 5.5字母(名义P=0.08),CST平均变化-119 μm(SD 112)vs -114 μm(SD 103)(名义P=0.71)。
关键数值与推荐
- FAc组白内障手术率27.9%,阿柏西普组6.6%。
- FAc组眼压升高发生率15.6%,阿柏西普组3.3%。
临床怎么用
- FAc植入剂可作为需减少注射负担的DME患者的基线治疗选择,但需权衡白内障和眼压升高的风险。
局限性
- 原文未报告主要终点的把握度计算、盲法实施细节及长期(超过18个月)安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The NEW DAY (ClinicalTrials.gov identifier, NCT04469595) study assessed the efficacy and safety of the fluocinolone acetonide (FAc; 0.19 mg) intravitreal implant as baseline therapy in diabetic macular edema (DME). DESIGN: Prospective, randomized, single-masked, active-controlled, multicenter, 18-month, phase 4 study. PARTICIPANTS: Adults with type 1 or 2 diabetes and center-involving DME confirmed by central subfield thickness (CST). METHODS: Treatment regimens were FAc implant followed by rescue supplemental injections of aflibercept if needed (2 mg/0.05 ml) for 17 months versus aflibercept loading dose (2 mg every 4 weeks for 5 consecutive doses) followed by rescue supplemental injections of aflibercept if needed (2 mg/0.05 ml) for 13 months. MAIN OUTCOME MEASURES: The primary end point was mean rescue supplemental injections of aflibercept needed during the study by treatment group. Additional outcomes included time to first rescue supplemental injection, best-corrected visual acuity (BCVA), CST, rates of cataract procedures, and increases in intraocular pressure (IOP). RESULTS: Five hundred seventeen participants were screened, and 306 participants randomized. Mean (standard deviation [SD]) rescue supplemental injections were 2.4 (3.2) with FAc and 2.5 (3.1) with aflibercept (P = 0.76; primary end point). Counting both protocol-mandated and rescue supplemental injections, the FAc group received fewer injections compared with the aflibercept group (mean [SD], 3.4 [3.2] vs. 7.2 [3.4] injections; nominal P < 0.001). Time to first rescue supplemental injection was longer with FAc than with aflibercept (mean [SD], 185.4 [97.9] days vs. 132.8 [94.0] days; nominal P < 0.001). Proportions of participants who did not receive rescue supplemental injections were similar (32.5% vs. 30.3%; nominal P = 0.68). Mean change in BCVA was similar between groups (1.8 letters vs. 5.5 letters; nominal P = 0.08), as was the change in CST (mean [SD], -119 [112] μm vs. -114 [103] μm; nominal P = 0.71). In the FAc group, 27.9% underwent a cataract procedure versus 6.6% in the aflibercept group. Increased IOP occurred in 15.6% and 3.3% of participants in the FAc and aflibercept groups, respectively. CONCLUSIONS: Although the primary end point of rescue supplemental injection superiority was not met, FAc-treated participants achieved similar visual and anatomic improvements as those receiving aflibercept with fewer than half the number of total injections throughout the study. Safety data results were consistent with previous FAc implant studies. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Singer MA, Wykoff CC, Riemann CD, et al. Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study. Ophthalmology. 2026. PMID: 41887289. doi:10.1016/j.ophtha.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。